Healthcare
Research Confirms That Serotonergic Antidepressants Like SSRIs, SNRIs Can Decrease Psilocybin’s Effects
More psychedelic community knowledge turns from folktale to fact.
A new study published in the Journal of Psychopharmacology found that serotonergic antidepressants like SSRIs and SNRIs can decrease psilocybin’s effects, Psychedelic Spotlight reports. Serotonergic antidepressants are often the first avenue for treating depression and include household names such as Prozac and Zoloft.
The research, published in June of 2023, comes from an online retrospective survey involving 2,153 people who had taken psilocybin mushrooms while also using an antidepressant and individuals who had used psilocybin within two years after stopping their antidepressants. The 611 respondents who had taken mushrooms alongside an antidepressant reported weaker-than-expected psilocybin effects, as did the 1,542 participants who had ceased their SSRI/SNRI medication. However, what’s notable is that the probability of weakened results was not significantly different between those who had discontinued antidepressants a week before taking shrooms and those who ceased taking their meds three to six months prior.
The study demonstrates that SNRI/SSRI antidepressants reduce the effects of psilocybin compared to non-serotonergic antidepressants—and that individuals who have stopped antidepressants may experience weaker effects up to three months after discontinuing their medication.
People who take psilocybin, the compound responsible for the hallucinogenic properties of magic mushrooms, have been talking about how antidepressants diminish the experience for years. However, what was, for so long, a discussion kept to music festivals and Reddit boards now has scientific backing. The confirmation comes at a time when psilocybin itself gains traction in the treatment of depression. Back in 2022, COMPASS Pathways unveiled the “largest randomized, controlled, double-blind study of psilocybin therapy ever completed,” which shows “significant” improvements to treatment-resistant depression (TRD) symptoms.
And recently, doctors from the University of Texas MD Anderson Cancer Center in Houston began a trial for psilocybin therapy to treat cancer-related anxiety and depression in patients by “examining the effects of psilocybin for patients with controlled advanced cancer on maintenance therapy experiencing challenges with mental health.”
While this is applaudable, as too many readers know, one does not need a cancer diagnosis to benefit from taking psilocybin for depression. While depressants like SSRIs can take up to six weeks to start working, psychedelics, such as psilocybin (not to mention ketamine), can reverse the effects of depression quickly and, hopefully, more effectively. As a 2020 study suggests, traditional antidepressants improve symptoms in about an extra 20 out of 100 people. Another study published in 2020 indicates that psilocybin can not only be an effective and quick-acting treatment for major depressive disorder, but more than half of the study’s participants stayed in remission from depression four weeks after treatment.
As a result, looking at statistics alone, many folks currently taking serotonergic antidepressants may be considering swapping out their Lexapro for psilocybin (which may also be more cost-effective in treating depression). So does one need to wean off their current medication before embarking on a psychedelic healing journey? When one takes two drugs together that both increase serotonin levels, such as an SSRI and MDMA, there is always the risk for serotonin toxicity, or serotonin syndrome, which can happen when drugs increase levels of the neurotransmitter serotonin between nerve cells past a safe level, leading to anything from nausea and anxiety to in rare cases coma and death. The latter, as so many people reading this who have taken psychedelics while on antidepressants can confirm, is pretty unheard of.
The research on antidepressants lowering the effects of psilocybin says that it’s generally safe to use serotonergic antidepressants pre-psilocybin treatment. However, be aware that SSRIs and SNRIs may not only diminish psilocybin’s effects but can do so for up to three months after stopping the antidepressant medication. So, if you’re on an SSRI or SSNI, it’s okay to try psilocybin for depression, but be aware that you may need three months to experience the full effect of your new medicine.
Cannabis & Policy
Supreme Court Raises Concern Over Steep Medicine Mark-Ups at Corporate Hospitals
The Supreme Court of India has questioned the sharp difference between the prices at which medicines reach retailers and the maximum retail prices charged to patients, particularly in corporate hospitals.
During a hearing on September 29, a bench of Justices Vikram Nath and Sandeep Mehta examined whether a uniform limit of 16% could be applied to medicine margins. The discussion followed the court’s earlier concern over a cancer medicine with a retailer price of about ₹2,700–₹3,000 but an MRP of ₹27,000.
Court Questions Wide Gap Between Retail Price and MRP
The Supreme Court focused on how such large differences between the Price to Retailer (PTR) and MRP can affect patients who have little choice over where they obtain medicines during hospital treatment.
The bench questioned why different pricing rules should apply to essential and non-essential medicines and asked whether a common 16% margin could be considered across pharmaceutical products. The issue remains under consideration and the court has not imposed such a cap at this stage.
Concerns Over In-House Hospital Pharmacies
The court also examined the purchasing practices of corporate hospitals.
According to the proceedings, patients admitted to some hospitals may be directed to obtain medicines from the facility’s own pharmacy. The bench raised concerns about situations in which hospitals may not accept medicines purchased from outside pharmacies or may decline to provide treatment assurances when patients bring their own drugs.
The issue becomes particularly significant for patients undergoing expensive or long-term treatments, where medicine costs can represent a substantial part of the overall bill.
Impact on Government Health Schemes
The Supreme Court also highlighted the potential effect of high medicine prices on publicly funded healthcare programmes.
Where treatment is reimbursed under government schemes, the court noted that taxpayers ultimately finance the medical expenses. If reimbursement is calculated using substantially inflated MRPs, the difference between procurement costs and the amount reimbursed could increase public expenditure.
The bench also pointed to a consumer-trust problem. If a medicine officially carries an MRP of ₹27,000 but a pharmacy offers it for around ₹3,000, patients may question whether the cheaper medicine is genuine.
Government Seeks Time to Examine the Issue
Solicitor General Tushar Mehta, appearing for the Centre, told the court that the government would need to work out a balanced approach.
The government has been asked to examine the issue with relevant officials before responding further. The court granted additional time for consultations rather than immediately introducing a new pricing rule.
The proceedings are part of a broader case concerning medicine pricing, generic prescriptions and regulation of medical costs. The Supreme Court’s official website lists Justice Vikram Nath and Justice Sandeep Mehta as sitting together in Court No. 2 on September 29, 2026.
Court’s Earlier Warning on Medicine Pricing
The latest hearing follows strong observations made by the Supreme Court earlier in September after it examined the pricing of cancer medicines.
The bench had highlighted an example where a medicine costing roughly ₹2,700 at the retailer level carried an MRP of ₹27,000. The court questioned how such a substantial price difference could be justified when patients are dependent on life-saving medicines.
The court also heard arguments that pharmaceutical manufacturers may not necessarily retain the entire difference between the retailer price and the final amount charged to patients, with significant margins potentially arising at later stages of the supply chain, including retail and hospital sales.
What Happens Next?
The Supreme Court has not yet ordered a nationwide 16% medicine-margin cap. Instead, it has asked the government to consider possible regulatory solutions and return with its response.
The matter is scheduled for further hearing on October 12, when the court is expected to consider the government’s position on medicine pricing and related issues.
Any eventual regulatory change could have implications for patients, hospitals, pharmacies, pharmaceutical companies and government-funded healthcare programmes. For now, the 16% figure remains a proposal raised during the court proceedings rather than an operative rule.
Economic Fraud
Fugitive Medicare Fraud Suspect Returned to US After Arrest in Türkiye
U.S. federal authorities have secured the return of a fugitive suspect accused of involvement in a massive Medicare fraud operation, following his arrest in Türkiye. The extradition marks a significant development in a major healthcare fraud investigation that allegedly cost the American healthcare system billions of dollars.
The suspect, Ibrahim Khaldoon Hilmi, is now in federal custody after spending more than a year outside the United States. Prosecutors are expected to move forward with criminal proceedings as investigators continue to examine what authorities describe as a sophisticated fraud network targeting public healthcare funds.
International Manhunt Ends with Arrest in Türkiye
According to federal investigators, Hilmi left the United States in May 2025 while authorities were building their case. Law enforcement agencies later tracked his location to Türkiye, where cooperation between U.S. and Turkish officials led to his detention.
Following the completion of legal and diplomatic procedures, the suspect was transferred to American custody. Officials described the operation as a successful example of international law enforcement collaboration in pursuing suspects accused of large-scale financial crimes.
A specialized FBI team reportedly traveled to Türkiye to coordinate the transfer and ensure the extradition process was completed smoothly.
Alleged Scheme Targeted Medicare Reimbursement System
Investigators allege that Hilmi played a central role in a fraudulent operation that exploited the Medicare reimbursement system through false claims and improper billing practices.
Authorities estimate that the alleged scheme involved financial losses equivalent to approximately ₹31,700 crore, making it one of the most significant healthcare fraud investigations in recent years.
While the allegations have yet to be tested in court, investigators believe the operation relied on complex financial transactions and coordinated activities designed to extract funds from a government healthcare program serving millions of beneficiaries.
Federal Agencies Expand Investigation
The case extends beyond a single suspect. Federal authorities are examining the potential involvement of additional individuals, businesses, and organizations believed to be connected to the alleged fraud network.
Investigators are reviewing banking records, financial transactions, corporate structures, and digital evidence to determine the full scope of the operation and identify any additional participants.
Officials indicated that tracing the movement of funds and uncovering potential links between entities remains a key focus of the ongoing investigation.
Healthcare Fraud Remains a Major Concern
Government agencies continue to treat Medicare fraud as a serious threat because it impacts taxpayer-funded healthcare resources intended for legitimate medical services.
Authorities argue that fraudulent claims can divert critical funding, increase administrative costs, and place additional pressure on public healthcare programs. As healthcare systems become increasingly digitized, fraud schemes have also become more sophisticated and difficult to detect.
Financial crime specialists note that modern healthcare fraud investigations often involve shell companies, layered transactions, and cross-border financial networks that require extensive forensic analysis.
Growing Importance of Global Law Enforcement Cooperation
The successful return of Hilmi highlights the increasing role of international cooperation in combating financial crime. Law enforcement agencies worldwide are relying more heavily on cross-border partnerships to locate and apprehend suspects who attempt to evade prosecution by relocating overseas.
Officials say such collaborations are essential as financial crimes become increasingly global in nature, involving multiple jurisdictions and complex international money flows.
Legal Proceedings Ahead
The U.S. Department of Justice is expected to present evidence against the suspect as court proceedings move forward. Prosecutors will seek to establish the extent of the alleged fraud and determine accountability among those involved.
The outcome of the case could influence future enforcement efforts aimed at protecting public healthcare programs and strengthening safeguards against large-scale financial misconduct.
For federal authorities, the extradition of Ibrahim Khaldoon Hilmi represents a major step in an ongoing campaign to crack down on healthcare fraud and recover public funds allegedly lost through criminal schemes.
Cyber Crime
Telangana Doctors Lose Nearly ₹30 Crore to Cyber Fraud Since September 2024
Cybercriminals have defrauded doctors across Telangana of nearly ₹30 crore since September 2024, prompting authorities to strengthen awareness campaigns and cybersecurity education within the healthcare sector.
The alarming figures were revealed during a cyber awareness programme organized by the Telangana Cyber Security Bureau (TGCSB) in Hyderabad. Senior officials warned that healthcare professionals are increasingly becoming targets of sophisticated online scams despite their educational and professional backgrounds.
Healthcare Professionals Under Growing Cyber Threat
Addressing representatives from various medical associations, TGCSB Director Shikha Goel highlighted the rising number of cybercrime incidents involving doctors and healthcare workers. She emphasized that cybercriminals are exploiting digital platforms to target individuals across all professions, including highly qualified medical practitioners.
Officials stressed that vigilance, awareness, and prompt reporting remain the strongest defenses against cyber fraud. The event focused on strengthening cooperation between law enforcement agencies and the medical fraternity to improve preparedness against evolving cyber threats.
More than 70 office-bearers from medical organizations across Telangana attended the session, including presidents, secretaries, treasurers, and senior representatives.
Investment Scams Responsible for Major Financial Losses
According to TGCSB data, at least 735 doctors have reported cybercrime-related incidents since September 2024, with total losses reaching approximately ₹29.88 crore.
Business and investment fraud emerged as the most damaging category, accounting for losses of ₹22.39 crore involving 127 victims. Investigators noted that fraudsters often lure professionals with promises of high returns, fake investment opportunities, and deceptive business schemes.
Authorities also reported a wide range of other cyber offences affecting doctors, including digital arrest scams, identity theft, impersonation fraud, fake advertisements, job-related scams, insurance fraud, cryptocurrency fraud, UPI-related cheating, matrimonial scams, and sextortion cases.
Authorities Stress Importance of Rapid Reporting
The Telangana Cyber Security Bureau urged victims to report cybercrime incidents immediately, especially during the critical “golden hour” after a fraudulent transaction occurs.
Officials explained that timely complaints through the national cybercrime helpline 1930 and the official cybercrime reporting portal can significantly improve the chances of freezing suspicious transactions and recovering stolen funds.
The bureau further warned that cybercriminals are employing increasingly advanced techniques to deceive victims, making awareness and quick action more important than ever.
Medical Associations Join Awareness Drive
Representatives from associations of paediatricians, cardiologists, dentists, orthopaedic surgeons, gynaecologists, and hospital administrators participated in the discussions. The groups pledged to work closely with authorities to spread cybersecurity awareness through hospitals, clinics, medical conferences, and professional training programmes.
Officials believe that expanding cyber awareness among healthcare professionals will play a key role in reducing financial fraud and strengthening digital security across the state’s medical community.
As cyber threats continue to evolve, law enforcement agencies are encouraging doctors and other professionals to remain cautious when responding to investment offers, unknown communications, and requests for sensitive financial information online.
-
Business3 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business3 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business3 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business3 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business3 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business3 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business3 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
